Observational analysis reveals safety and clinical improvement in autoimmune diseases using point-of-care CAR-T therapy, suggesting potential for broader immune modulation.
Key Points
POC anti-CD19 CAR-T therapy demonstrates promise in treating autoimmune diseases with manageable toxicity and risk stratification.
The primary focus was on safety, with clinical observations indicating significant improvements in 3 RA patients.
Autologous stem cell transplantation history may impact treatment effectiveness and safety profiles in systemic sclerosis patients.
This approach may enable new therapeutic options for patients with treatment-refractory autoimmune conditions, warranting further study.